← Leaderboards
Sherry McKee
Yale University
$26,885,003
Attributed
$31,756,724
Total exposure
37
Grants
30
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.9M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$49,202,785 · 40
By mechanism
P50$14,116,026 · 12
U54$14,109,877 · 6
R01$13,290,193 · 7
U01$2,828,440 · 1
R21$1,348,805 · 3
RL1$1,311,476 · 1
Top collaborators
- Carlos M Grilo5 shared
- Kelly P Cosgrove2 shared
- Andrew Hyland2 shared
- Walter Mcrainey Roberts2 shared
- Christian S Hendershot1 shared
- Andrea C King1 shared
- Joseph P Schacht1 shared
Most similar at Yale University
Same institution · by research overlap
- Hedy Kober$11,564,837
- Robert Henry Roth$12,108,184
- Marina R. Picciotto$36,006,961
- Thomas Richard Kosten$19,160,340
- Marc Nigel Coutanche$1,405,219
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsDesignWomanLaboratoriesStressSmokingSmoking CessationCravingGuanfacineAlcoholsNicotineSmokerDouble-Blind MethodInvestigationPsychological ReinforcementAttenuatedNoradrenergicRelapseDrinkingPreclinical StudyPlacebosAlcohol Use DisorderAlcohol ConsumptionFunding
Grant awards (116)
Multi Site Randomized Trial of a GLP-1/GIP Receptor Agonist for Smoking Cessation$2,828,440
U01 · FY2025 · DA
Yale-SCORE on Sex Differences in Alcohol Use Disorder$1,500,000
U54 · FY2025 · AA · contact PI
Characterizing initial recovery from alcohol use disorder and predicting heavy drinking using mobile biosensors$684,745
R01 · FY2025 · AA · contact PI
Developing a novel human laboratory paradigm for AUD medication screening: Modeling the ability to resist drinking and heavy drinking$366,406
R34 · FY2025 · AA · contact PI
PROJECT 1: Phase 2a dose-response study of apremilast in females and males with alcohol use disorder$250,001
U54 · FY2025 · AA · contact PI
Yale-SCORE Leadership Administrative Core$249,999
U54 · FY2025 · AA · contact PI
YALE-SCORE ON SEX DIFFERENCES IN ALCOHOL USE DISORDER$1,675,000
U54 · FY2024 · AA · contact PI
Characterizing initial recovery from alcohol use disorder and predicting heavy drinking using mobile biosensors$686,518
R01 · FY2024 · AA · contact PI
Developing a novel human laboratory paradigm for AUD medication screening: Modeling the ability to resist drinking and heavy drinking$366,406
R34 · FY2024 · AA · contact PI
PROJECT 1: Targeting stress-reactivity and noradrenergic mechanisms for sex-appropriate alcohol use disorder treatment.$337,751
U54 · FY2024 · AA · contact PI
Leadership Administrative Core$158,530
U54 · FY2024 · AA · contact PI
Enhancing dissemination and career development in sex and gender translational science in alcohol use$1
R13 · FY2024 · AA · contact PI
YALE-SCORE ON SEX DIFFERENCES IN ALCOHOL USE DISORDER$1,675,000
U54 · FY2023 · AA · contact PI
Leadership Administrative Core$467,776
U54 · FY2023 · AA · contact PI
PROJECT 1: Targeting stress-reactivity and noradrenergic mechanisms for sex-appropriate alcohol use disorder treatment.$271,659
U54 · FY2023 · AA · contact PI
Enhancing dissemination and career development in sex and gender translational science in alcohol use$12,500
R13 · FY2023 · AA · contact PI
YALE-SCORE ON SEX DIFFERENCES IN ALCOHOL USE DISORDER$1,675,000
U54 · FY2022 · AA · contact PI
Phase 2 study examining efficacy and mechanisms of combining varenicline and guanfacine for smoking cessation in women and men$795,030
R01 · FY2022 · DA · contact PI
Leadership Administrative Core$673,843
U54 · FY2022 · AA · contact PI
PROJECT 1: Targeting stress-reactivity and noradrenergic mechanisms for sex-appropriate alcohol use disorder treatment.$344,262
U54 · FY2022 · AA · contact PI
YALE-SCORE ON SEX DIFFERENCES IN ALCOHOL USE DISORDER$1,675,000
U54 · FY2021 · AA · contact PI
Phase 2 study examining efficacy and mechanisms of combining varenicline and guanfacine for smoking cessation in women and men$795,030
R01 · FY2021 · DA · contact PI
Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder$683,698
R01 · FY2021 · DK
Leadership Administrative Core$653,778
U54 · FY2021 · AA · contact PI
PROJECT 1: Targeting stress-reactivity and noradrenergic mechanisms for sex-appropriate alcohol use disorder treatment.$229,801
U54 · FY2021 · AA · contact PI
Yale-SCORE NIMH Data Archive$108,091
U54 · FY2021 · AA · contact PI
YALE-SCORE ON SEX DIFFERENCES IN ALCOHOL USE DISORDER$1,675,000
U54 · FY2020 · AA · contact PI
Phase 2 study examining efficacy and mechanisms of combining varenicline and guanfacine for smoking cessation in women and men$754,959
R01 · FY2020 · DA · contact PI
Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder$714,857
R01 · FY2020 · DK
PROJECT 1: Targeting stress-reactivity and noradrenergic mechanisms for sex-appropriate alcohol use disorder treatment.$344,261
U54 · FY2020 · AA · contact PI
Leadership Administrative Core$145,125
U54 · FY2020 · AA · contact PI
Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder$726,062
R01 · FY2019 · DK
Sex-Appropriate Treatment Development for Alcohol Use Disorders$500,000
P01 · FY2019 · AA · contact PI
Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder$737,017
R01 · FY2018 · DK
Sex-Appropriate Treatment Development for Alcohol Use Disorders$500,000
P01 · FY2018 · AA · contact PI
PROJECT 3: EVALUATION OF GUANFACINE ON DRINKING BEHAVIOR IN WOMEN AND MEN WITH ALCOHOL USE DISORDERS$74,143
P01 · FY2018 · AA · contact PI
Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder$753,653
R01 · FY2017 · DK
Yale SCOR on Gender-Sensitive Treatment for Tobacco Dependence$525,000
P50 · FY2017 · DA · contact PI
Does Guanfacine, an alpha2 adrenergic agonist, attenuate stress-induced drinking?$374,625
R01 · FY2017 · AA · contact PI
Project-003$142,194
P50 · FY2017 · DA · contact PI
Project-001$134,514
P50 · FY2017 · DA · contact PI
Project-002$129,012
P50 · FY2017 · DA · contact PI
Core-001$61,382
P50 · FY2017 · DA · contact PI
Admin-Core-001$57,898
P50 · FY2017 · DA · contact PI
Yale SCOR on Gender-Sensitive Treatment for Tobacco Dependence$1,165,950
P50 · FY2016 · DA · contact PI
Does Guanfacine, an alpha2 adrenergic agonist, attenuate stress-induced drinking?$374,625
R01 · FY2016 · AA · contact PI
Sex Differences in Dopamine Release in Tobacco Smokers$321,692
P50 · FY2016 · DA · contact PI
Acetylcholine-norepinephrine interactions and their implications for the effects$313,452
P50 · FY2016 · DA · contact PI
Effect of an alpha-2a adrenergic agonist on stress-induced smoking and smoking$234,018
P50 · FY2016 · DA · contact PI
SCOR Service Core (Core B)$152,267
P50 · FY2016 · DA · contact PI
Scientific and Administrative Core$144,521
P50 · FY2016 · DA · contact PI
Yale SCOR on Gender-Sensitive Treatment for Tobacco Dependence$1,170,150
P50 · FY2015 · DA · contact PI
Phase-II Clinical Trial Evaluating Guanfacine for Smoking Cessation$806,932
R01 · FY2015 · DA · contact PI
Does Guanfacine, an alpha2 adrenergic agonist, attenuate stress-induced drinking?$363,386
R01 · FY2015 · AA · contact PI
Sex Differences in Dopamine Release in Tobacco Smokers$321,646
P50 · FY2015 · DA · contact PI
Acetylcholine-norepinephrine interactions and their implications for the effects$311,870
P50 · FY2015 · DA · contact PI
Effect of an alpha-2a adrenergic agonist on stress-induced smoking and smoking$241,344
P50 · FY2015 · DA · contact PI
SCOR Service Core (Core B)$151,498
P50 · FY2015 · DA · contact PI
Scientific and Administrative Core$143,792
P50 · FY2015 · DA · contact PI
Yale SCOR on Gender-Sensitive Treatment for Tobacco Dependence$1,201,589
P50 · FY2014 · DA · contact PI
Phase-II Clinical Trial Evaluating Guanfacine for Smoking Cessation$711,972
R01 · FY2014 · DA · contact PI
Does Guanfacine, an alpha2 adrenergic agonist, attenuate stress-induced drinking?$374,625
R01 · FY2014 · AA · contact PI
Sex Differences in Dopamine Release in Tobacco Smokers$329,860
P50 · FY2014 · DA · contact PI
Acetylcholine-norepinephrine interactions and their implications for the effects$319,116
P50 · FY2014 · DA · contact PI
Effect of an alpha-2a adrenergic agonist on stress-induced smoking and smoking$240,840
P50 · FY2014 · DA · contact PI
Does doxazosin attenuate stress-induced smoking and improve clinical outcomes?$208,125
R21 · FY2014 · DA · contact PI
Scientific and Administrative Core$157,967
P50 · FY2014 · DA · contact PI
SCOR Service Core (Core B)$153,806
P50 · FY2014 · DA · contact PI
Phase-II Clinical Trial Evaluating Guanfacine for Smoking Cessation: Administrative Supplement$108,950
R01 · FY2014 · DA · contact PI
Yale SCOR on Gender-Sensitive Treatment for Tobacco Dependence$1,170,462
P50 · FY2013 · DA · contact PI
Phase-II Clinical Trial Evaluating Guanfacine for Smoking Cessation$655,770
R01 · FY2013 · DA · contact PI
Sex Differences in Dopamine Release in Tobacco Smokers$394,906
P50 · FY2013 · DA · contact PI
Acetylcholine-norepinephrine interactions and their implications for the effects$385,617
P50 · FY2013 · DA · contact PI
Effect of an alpha-2a adrenergic agonist on stress-induced smoking and smoking$319,104
P50 · FY2013 · DA · contact PI
SCOR Service Core (Core B)$193,149
P50 · FY2013 · DA · contact PI
Scientific and Administrative Core$184,264
P50 · FY2013 · DA · contact PI
Yale SCOR on Gender-Sensitive Treatment for Tobacco Dependence$1,229,819
P50 · FY2012 · DA · contact PI
Sex Differences in Dopamine Release in Tobacco Smokers$331,994
P50 · FY2012 · DA · contact PI
Acetylcholine-norepinephrine interactions and their implications for the effects$326,042
P50 · FY2012 · DA · contact PI
Effect of an alpha-2a adrenergic agonist on stress-induced smoking and smoking$272,896
P50 · FY2012 · DA · contact PI
Does doxazosin attenuate stress-induced smoking and improve clinical outcomes?$249,125
R21 · FY2012 · DA · contact PI
SCOR Service Core (Core B)$153,343
P50 · FY2012 · DA · contact PI
Scientific and Administrative Core$145,544
P50 · FY2012 · DA · contact PI
Dose ranging study of varenicline on human alcohol self-administration behavior$320,053
R01 · FY2011 · AA · contact PI
Does Tobacco Legislation Reduce Alcohol Consumption?$259,102
R21 · FY2011 · AA · contact PI
Modeling Stress-Precipitated Smoking Lapse for Medication Development (9 of 14)$233,866
RL1 · FY2011 · DA · contact PI
Modeling Stress-Precipitated Smoking Lapse for Medication Development (9 of 14)$2,830
RL1 · FY2011 · DA · contact PI
Dose ranging study of varenicline on human alcohol self-administration behavior$333,215
R01 · FY2010 · AA · contact PI
Does Tobacco Legislation Reduce Alcohol Consumption?$242,629
R21 · FY2010 · AA · contact PI
Modeling Stress-Precipitated Smoking Lapse for Medication Development (9 of 14)$241,099
RL1 · FY2010 · DA · contact PI
Dose ranging study of varenicline on human alcohol self-administration behavior$381,551
R01 · FY2009 · AA · contact PI
Do Treatments for Smoking Cessation Reduce Alcohol Drinking?$286,094
R01 · FY2009 · AA · contact PI
Modeling Stress-Precipitated Smoking Lapse for Medication Development (9 of 14)$243,533
RL1 · FY2009 · DA · contact PI
Modeling Stress-Precipitated Smoking Lapse for Medication Development (9 of 14)$82,745
RL1 · FY2009 · DA · contact PI
Modeling Stress-Precipitated Smoking Lapse for Medication Development (9 of 14)$16,370
RL1 · FY2009 · DA · contact PI
Do Treatments for Smoking Cessation Reduce Alcohol Drinking?$286,094
R01 · FY2008 · AA · contact PI
Modeling Stress-Precipitated Smoking Lapse for Medication Development (9 of 14)$243,533
RL1 · FY2008 · DA · contact PI
MODELING SMOKING LAPSE BEHAVIOR FOR DRUG DEVELOPMENT$202,743
P50 · FY2008 · AA · contact PI
Do Treatments for Smoking Cessation Reduce Alcohol Drinking?$286,094
R01 · FY2007 · AA · contact PI
Modeling Stress-Precipitated Smoking Lapse for Medication Development (9 of 14)$247,500
RL1 · FY2007 · DA · contact PI
MODELING SMOKING LAPSE BEHAVIOR FOR DRUG DEVELOPMENT$192,984
P50 · FY2007 · AA · contact PI
Smoking cessation treatments and alcohol drinking$294,638
R01 · FY2006 · AA · contact PI
Negative Affect and Smoking Behavior in Women and Men$210,326
R21 · FY2006 · DA · contact PI
MODELING SMOKING LAPSE BEHAVIOR FOR DRUG DEVELOPMENT$162,209
P50 · FY2006 · AA · contact PI
Investigating Tobacco & Alcohol Use Behaviors Across the Continuum of Use$71,040
R03 · FY2006 · AA · contact PI
Negative Affect and Smoking Behavior in Women and Men$179,498
R21 · FY2005 · DA
MODELING SMOKING LAPSE BEHAVIOR FOR DRUG DEVELOPMENT$168,288
P50 · FY2005 · AA
Investigating Tobacco &Alcohol Use Behaviors$72,750
R03 · FY2005 · AA
EFFECT OF NICOTINE REPLACEMENT ON SMOKING DURING ALCOHOL SELF-ADMINISTRATION$7,057
M01 · FY2005 · RR
NICOTINE RECEPTOR ANTAGONIST ON SMOKING BEHAVIOR IN SCHIZOPHRENICS$4,852
M01 · FY2005 · RR
EFFECT OF ALCOHOL ON RELAPSE TO TOBACCO USE$2,206
M01 · FY2005 · RR
MODELING SMOKING LAPSE BEHAVIOR FOR DRUG DEVELOPMENT$157,284
P50 · FY2004 · AA
Modeling the Effect of Alcohol on Relapse to Tobacco$45,250
M01 · FY2004 · RR
Alcohol Self-Administration: Effect of Nicotine Replacem$38,785
M01 · FY2004 · RR
Alcohol Self-Administration/Effect/Nicotine Replacement$68,804
R03 · FY2003 · AA
Alcohol Self-Administration/Effect/Nicotine Replacement$67,768
R03 · FY2002 · AA